A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma

V. Gruenwald,Ludwig Wilkens,M. Gebel,T. Wirth,Tim F. Greten,Stefan Kubicka,M.P. Manns,Arnold Ganser,Nisar P. Malek

A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma

2006

V. Gruenwald
Ludwig Wilkens
M. Gebel
T. Wirth
Tim F. Greten
Stefan Kubicka
M.P. Manns
Arnold Ganser
Nisar P. Malek

14079 Background: The majority of hepatocellular carcinomas (HCC) express the epidermal growth factor receptor (EGFR). The monoclonal anti-EGFR antibody cetuximab blocks EGFR activation. In the cur...

Keywords:

Cetuximab
Cancer research
Hepatocellular carcinoma
Oncology
Medicine
Internal medicine
Antibody
open label study
Epidermal growth factor receptor
Monoclonal

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations